{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T08:29:33Z","timestamp":1700123373578},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.2169\/internalmedicine.6664-20","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T22:09:48Z","timestamp":1613945388000},"page":"2437-2443","source":"Crossref","is-referenced-by-count":4,"title":["Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-na\u00efve Hepatitis C Virus Infection"],"prefix":"10.2169","volume":"60","author":[{"given":"Tasuku","family":"Hara","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Iwai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Okuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Komaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakagami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374, 2009.","DOI":"10.1002\/hep.22759"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 166: 637-648, 2017.","DOI":"10.7326\/M16-2575"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378: 354-369, 2018.","DOI":"10.1056\/NEJMoa1702417"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre Phase 3 trial. Lancet Infect Dis 17: 1062-1068, 2017.","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"5. Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 67: 505-513, 2018.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, sever renal impairment, or genotype 3 infection. J Gastroenterol 53: 566-575, 2018.","DOI":"10.1007\/s00535-017-1396-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 63: 503-514, 2015.","DOI":"10.1016\/j.jhep.2015.04.016"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Takikawa K, Onji M, Takamori Y, et al. Proposal of diagnostic criteria of drug induced hepatic injury in DDW-J2004 workshop. Kanzo 46: 85-90, 2005 (in Japanese).","DOI":"10.2957\/kanzo.46.85"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol 47: 849-861, 2012.","DOI":"10.1007\/s00535-012-0624-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hammami MB, Aboushaar R, Alsabbagh E. Glecaprevir\/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection. BMJ Case Rep 12: e231744, 2019.","DOI":"10.1136\/bcr-2019-231744"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yoon JH, Kim SM, Kang G, Kim HJ, Jun CH, Choi SKl. A case report of glecaprevir\/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore) 98: e17343, 2019.","DOI":"10.1097\/MD.0000000000017343"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69: 461-511, 2018.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hepatitis C Guideline 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection. Clin Infect Dis 67: 1477-1492, 2018.","DOI":"10.1093\/cid\/ciy585"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Drafting Committee for Hepatitis Management Guidelines the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection; 2019 update. Hepatol Res 50: 791-816, 2020.","DOI":"10.1111\/hepr.13503"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gane E, Poordad F, Zadeikis N, et al. Safety and pharmacokinetics of glecapirevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease. Clin Infect Dis 69: 1657-1664, 2019.","DOI":"10.1093\/cid\/ciz022"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Suleiman AA, Lin CW, Liu W, et al. Population pharmacokinetics of glecapirevir\/pibrentasvir in HCV-infected Japanese subjects in phase 3 CERTAIN-1 and CERTAIN-2 trials. J Clin Pharmacol 60: 331-339, 2020.","DOI":"10.1002\/jcph.1524"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144: 1419-1425, 2013.","DOI":"10.1053\/j.gastro.2013.02.006"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shin J, Hunt CM, Suzuki A, Papay JI, Beach KJ, Cheetham TC. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical report data. Pharmacoepidemiol Drug Saf 22: 190-198, 2013.","DOI":"10.1002\/pds.3388"},{"key":"19","unstructured":"19. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 148: 1340-1352, 2015."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lu RJ, Zhang Y, Tang FL, et al. Clinical characteristics of drug-induced liver injury and related risk factors. Exp Ther Med 12: 2606-2616, 2016.","DOI":"10.3892\/etm.2016.3627"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mucke MM, Backus LI, Mucke VT, et al. Hepatitis B reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 3: 172-180, 2018.","DOI":"10.1016\/S2468-1253(18)30002-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug 4: 489-499, 2005.","DOI":"10.1038\/nrd1750"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res 49: 105-110, 2019.","DOI":"10.1111\/hepr.13288"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 71: 684-700, 2011.","DOI":"10.1111\/j.1365-2125.2010.03774.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Fujiwara K, Abe R, Yasui S, Yokosuka O, Kato N, Oda S. High recovery rate of consciousness by high-volume filtrate hemodiafiltration for fulminant hepatitis. Hepatol Res 49: 224-231, 2019.","DOI":"10.1111\/hepr.13255"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 51: 629-650, 2016.","DOI":"10.1007\/s00535-016-1216-y"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/15\/60_6664-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T12:19:19Z","timestamp":1671365959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/15\/60_6664-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":26,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6664-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,1]]},"article-number":"6664-20"}}